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Abstract 
Background:  Large-scale epidemiological studies support an important role for 
susceptibility genes in the pathogenesis of ischemic stroke, with PDE4D identified as the first 
gene predisposing to ischemic stroke.  Several single nucleotide polymorphisms (SNPs) within 
the PDE4D gene have been implicated in the pathogenesis of stroke.
Aim:  Undertake a multivariate analysis of six SNPs within the PDE4D gene in a previously 
defined Australian stroke cohort, to determine whether these SNPs have an association with 
ischemic stroke.
Methods: This case-control study was performed using an existing genetic database of 180 
ischemic stroke patients and 301 community controls, previously evaluated for cerebrovascular 
risk factors (hypertension, hypercholesterolemia, diabetes, paroxysmal atrial fibrillation, 
smoking and history of stroke in a first degree relative).  Based on previously reported 
associations with large vessel disease, ischemic stroke, cardioembolic stroke or a mixture of 
these, six SNPs in the PDE4D gene were selected for study, these being SNPs 13, 19, 
rs152312, 45, 83 and 87, based on previously utilised DeCODE nomenclature.  SNPs were 
genotyped using a sequence-specific polymerase chain reaction (PCR) method and gel 
electrophoresis.  Logistic regression was undertaken to determine the relevance of each 
polymorphism to stroke.  Further analysis was undertaken to determine the risk of stroke 
following stratification for stroke subtype and etiology.
Results:  Significant odds ratios were found to be associated with cardioembolic strokes in 
two SNPs: rs152312 and SNP 45 (p<0.05).
Conclusion: Our findings demonstrated an association between cardioembolic stroke and 
PDE4D SNPs rs152312 and 45.  No significant association was found for the other 4 SNPs 
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investigated within the PDE4D gene.  We propose that the results from this Australian 
population support the concept that a large prospective international study is required to 
investigate the role of PDE4D in the cardiogenic cause of ischemic stroke.
Introduction
Large-scale epidemiological studies support an important role for susceptibility genes in the 
pathogenesis of ischemic stroke (1-3).  A unique Icelandic familial stroke study identified 
Phosphodiesterase 4D (PDE4D) as the first mapping of a gene to predispose to ischemic 
stroke, independent of conventional risk factors (4, 5).  Vascular endothelial cells act as 
gatekeepers to control the infiltration of inflammatory cells via adhesion molecules that play a 
central role in the recruitment of inflammatory cells (6).  PDE4D degrades 3',5'-cyclic AMP 
(cAMP), which is a key signalling molecule involved in the inflammatory responses of 
vascular cells (6, 7).  Inhibitors of PDE4 have been reported to increase cAMP levels and 
adhesion in vascular endothelial cells (8, 9) and decrease migration of vascular smooth muscle 
cells (10), as well as inhibiting the expression of the cell-adhesion molecule E-selectin on 
human lung microvascular endothelial cells (11).  Because of these effects, PDE4D has been 
postulated to contribute to vascular disease through its role in processes important in the 
pathogenesis of atherosclerosis, for example, through inflammation and plaque instability (5, 
12).
However, the findings of many subsequent individual studies have not substantiated the 
original Icelandic association, with meta-analysis of PDE4D SNPs casting doubt on the 
conclusion of individual studies (13).  In this meta-analysis, based on all PDE4D studies prior 
to 2008, Bevan et al. found that although there were several significant associations between 
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PDE4D and ischemic stroke, all became non-significant once the original Gretarsdottir et al. 
study (5) was excluded.  When they pooled studies on white populations only, there were 
significant associations between several SNPs and ischemic stroke subtypes, particularly SNP 
45 and combined large vessel disease and cardioembolic stroke subgroups.  Nonetheless, when 
the original study by Gretarsdottir et al. was excluded, the results again became non-
significant.  Bevan et al. concluded that meta-analysis did not support studies replicating the 
original Gretarsdottir et al. study for any association of PDE4D with ischemic stroke (13).  
Since the data they presented could not totally exclude a link between PDE4D and ischemic 
stroke, they proposed that any association that may exist was likely to be weak and possibly 
restricted to specific populations: the studies analysed had been undertaken on populations in 
Iceland, USA, Greece, Japan, Sweden, Pakistan, Australia, Netherlands, United Kingdom and 
Germany. 
A recent review (14) also commented on the relevance of differing findings in different 
populations, noting that many questions with respect to the role of PDE4D in stroke 
development remain unresolved.  Genetic stroke studies from North India (15) and South India 
(16) showed that different populations demonstrated different linkages between SNP 83 and 
ischemic stroke, and SNP 83 with Large Artery Atherosclerosis and Small Artery Occlusion, 
respectively.  Two separate recent medium-sized studies of Shanghai Chinese (17) and Beijing 
Chinese (18), found an association between SNP 83 and the combined cardiogenic and carotid 
stroke subgroups and of SNP 83 with atherothrombotic stroke, respectively.  The only study of 
an Australian population in Western Australia has not been replicated independently (19).  We 
initiated an independent South Australian study seeking an association between six PDE4D 
SNPs, ischemic stroke and stroke risk factors in a previously defined South Australian stroke 
cohort (21) and sought to determine the relevance of these polymorphisms to either 
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cardioembolic stroke or other stroke subtypes.  We chose the six SNPs based on positive 
associations in previous studies, a SNP frequency in the population greater than 10% and 
underlying biological plausibility.  Three of these SNPs (45, 83 and 87) were studied 
independently by the Western Australian researchers (19).
Methods
We genotyped DNA from 180 patients with acute ischemic stroke and 301 age- and gender-
matched controls, sourced from our earlier prospective case-control study and using the same 
method (21), with research ethics approval. Patients for this study were admitted with acute
ischemic stroke to one of five major hospitals within metropolitan Adelaide, South Australia
and were invited to participate in the study. All participants were evaluated for known 
cerebrovascular risk factors, including age, gender, ethnicity, hypertension, 
hypercholesterolemia, diabetes mellitus, past history of stroke, smoking history, family history 
of stroke and atrial fibrillation (AF).  The diagnosis of ischemic stroke was made by a 
neurologist (J.J.) in accordance with the World Health Organization definition (20).  All 
patients underwent brain computerized tomography in order to allow exclusion of intracerebral 
and subarachnoid hemorrhage.
Stroke subtype was determined using the Oxford Community Stroke Project criteria (22). 
Subjects were further classified into lacunar syndrome versus non-lacunar syndrome (i.e. total 
anterior circular syndrome, partial anterior circulation syndrome and posterior circulation 
syndrome) and also cardioembolic versus non-cardioembolic causes, based on the presence of 
AF, determined by review of the twelve lead electrocardiograms (ECG) performed on 
admission for all patients.  Atrial fibrillation was also deemed present if there was a reported 
PDE4D Polymorphisms & Cardioembolic Stroke 7
history of paroxysmal AF, regardless of the cardiac rhythm on ECG.  Unless other 
investigations (e.g. high grade internal carotid artery stenosis or stroke affecting multiple
cerebrovascular territories in the absence of an identifiable cause) showed otherwise, all 
patients with AF were recorded as cardioembolic in origin.  Patients with cardiac valve 
prostheses were also coded as cardioembolic in origin if there was no clinical or radiological 
evidence of an alternate thrombotic source.  Full study demographics and risk factor 
characteristics have been described previously (21) and are summarized in Table 1.
The control group consisted of non-hospitalized subjects from metropolitan Adelaide with no 
personal history of cerebrovascular disease.  Controls, selected by random sampling of the 
South Australian electronic telephone directory, were group-matched with patients for age 
(within 5-year strata) and gender.
In this study, 201 consecutive patients with acute ischemic stroke were asked to participate. 
182 (90.5%) agreed to participate, and 137 (75%) of these were first presentation ischemic 
stroke.  No significant differences were observed between the two groups in terms of 
demographic variables (Table 1).  Amongst the known risk factors examined, atrial fibrillation 
was found to be associated with the highest risk of ischemic stroke, with 23% of cases versus 
3% of controls affected (OR: 8.5; 95% CI: 4.1 to 17.4).  A history of smoking within the past 5 
years (OR: 3.1; 95% CI: 1.9 to 5.2) and diabetes mellitus (OR: 2.7; 95% CI: 1.6 to 4.4) were 
also observed to be significantly associated with ischemic stroke.  No association was found 
between ischemic stroke and a history of stroke in a first-degree relative, hypertension, 
hypercholesterolemia (Table1), or for the use of antihypertensive, antiplatelet, and lipid-
lowering medication (results not shown).  Two patients died after enrolment in the study and 
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before venous blood sampling, so that genetic analysis could not be performed; hence 180 
patients remained for the full study.
Six SNPs were chosen based on positive associations in previous studies, a SNP frequency 
greater than 10% and underlying biological plausibility.  We kept the DeCODE nomenclature 
from the original Icelandic study mapping the PDE4D gene: SNPs 13, 19, rs152312, 45, 83 and 
87 (5).  These SNPs are located in a region near the alternative forms of exon 1 in the gene. 
Allele-specific and consensus primers were designed using sequences from the Entrez Human 
Genome public database.  Specific sequences were synthesised by GeneWorks Pty Ltd, 
Adelaide, South Australia and the resultant PCR products were confirmed by sequencing 
(Department of Molecular Pathology, Institute of Medical and Veterinary Science, Adelaide, 
South Australia).  Genotyping and quality control methods have been described previously (21, 
23).  An internal positive control was run for every PCR well, consisting of a pair of primers 
specific to an invariant section of the HLA DRB1 gene, to ensure that negative alleles were not 
due to failed polymerase reactions.
Power was estimated (with Win Episcope [ver.2, http://www.clive.ed.ac.uk/winepiscope/]) 
using frequencies reported for two representative SNPs (45 and 87) with lower and higher at-
risk frequencies, respectively (5).  Given a control population allele frequency of 78% (SNP 
45, and hence an at-risk frequency of 22%) with 95% confidence levels and 80% beta, 472 
subjects were required to detect a minimum odds ratio (OR) of 2.0 (minimum detectable OR 
<0.81 or >1.52).  Using the control population allele frequency of 48.4% (SNP 87) with 95% 
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confidence intervals (C.I.) and 80% beta, 270 subjects were required to detect a minimum OR 
of 2.0 (minimum OR <0.79 or >1.36).  
All statistics were analyzed with the R statistical language (24).  The relevance of each 
polymorphism was assessed by logistic regression of allelotypes and genotypes, for all strokes 
and stroke subtypes, adjusting for important vascular risk factors.  Hardy-Weinberg 
equilibrium was also assessed for each SNP.  Confounders, defined as extraneous factors or 
variables that partially (or wholly) account for the observed effect of a risk factor on the 
occurrence of stroke, included age, gender, family history of stroke, hypertension, diabetes, 
smoking, cholesterol and atrial fibrillation.  Confounders causing ±10% or more change in the 
odds ratio in the regressions of stroke incidence on SNPs were considered ‘important’ (25).  
Confidence intervals were also calculated to assess the significance of the odds ratio.









Age (years, mean +/- 1 SD) 73.4 +/- 11.6 73.6 +/- 12 0.8
Females 134 (45)   80 (44)
1.0 (0.7 – 1.5) 0.9
Males 167 (55) 102 (56)
White 299 (99.7) 178 (98)
6.7 (0.8 – 60.6) 0.09
Non-white     1 (0.3)     4 (2)
Family history of stroke 100 (33)   60 (33)
1.0 (0.7 – 1.5) 0.95
No family history of stroke 201 (67) 122 (67)
Hypertension 137 (46)   85 (52)
1.3 (0.9 – 1.9) 0.2
No hypertensive 164 (54)   87 (48)
Hypercholesterolemia 119 (40)   65 (36)
0.9 (0.6 – 1.2) 0.4
No hypercholesterolemia 182 (60) 117 (64)
Atrial fibrillation   10 (3)   41 (23)
8.5 (4.1 – 17.4) <0.0001
No atrial fibrillation 291 (97) 141 (77)
Smoking in last 5 years   30 (10) 47 (26)
3.1 (1.9 – 5.2) <0.0001
No smoking in last 5 years 271 (90) 135 (74)
Diabetes mellitus   33 (11)   45 (25)
2.7 (1.6 – 4.4) <0.0001
No diabetes mellitus 268 (89) 137 (75)
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Totals 301 182
TABLE 1. Demographic Characteristics and Prevalence of Risk Factors for Patients 
with Ischemic Stroke and Controls.
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PDE4D genotype: n SNP 13 SNP 19 rs152312 SNP 45 SNP 83 SNP 87
Minor Allele: G G T A T C
Frequency in Controls: 301 45.3% 26.7% 10.3% 17.6% 42.5% 48.3%
Ischemic Stroke: 180 43.1% 28.6% 12.2% 15.3% 43.9% 50.0%
Stroke Subtypes
Lacunar Stroke: 44 47.7% 25.0% 9.1% 14.8% 47.7% 52.3%
Non-Lacunar Stroke: 136 41.5% 29.8% 13.2% 15.4% 42.6% 49.3%
Total: 180
Cardioembolic Stroke: 24 22.9% 31.3% 27.1% 2.1% 47.9% 58.3%
Non-Cardioembolic
Stroke: 
156 45.9% 28.3% 9.9% 17.2% 43.6% 49.0%
Total: 180
TABLE 2.  Minor allele frequency of PDE4D SNPs.
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Results
All SNPs showed accordance with expected Hardy-Weinberg equilibrium ratios.  Data in Table 
1 show that atrial fibrillation, smoking and diabetes were significant confounders affecting the 
risk of stroke in this population group, as reported previously (21). 
The minor allele frequencies we found for each SNP in the control population for all patients 
with ischemic stroke and for distinctive subtypes are presented in Table 2.  For all stroke and 
for the subtypes classified as lacunar stroke, non-lacunar stroke and non-cardioembolic stroke, 
no significant associations with these six PDE4D SNPs were found.  However, for the 
cardioembolic stroke subtype, an association was found with two of the SNPs, rs152312 and 
SNP 45, as shown in Table 3.  Significant confounding factors for cardioembolic stroke and 
rs152312 were atrial fibrillation, hypertension, male gender and diabetes, whilst those for SNP 
45 were atrial fibrillation and smoking. However, the data for both of these SNPs remained 
significant, even after adjustment for these confounding factors.  
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SNP & allele Stroke Subtype Odds Ratio 95% C.I. p value
rs152312 T v C
cardioembolic stroke (n=24) 3.25 (1.57, 6.36) 0.002
adjusted for significant 
variables *
3.85 (1.43, 10.13) 0.007
45 A v G
cardioembolic stroke (n=24) 0.11 (0.005, 0.52) 0.002
adjusted for significant 
variables ^
0.08 (0.004, 0.50) 0.03
TABLE 3.  Association of PDE4D rs152312 and SNP 45 alleles with cardioembolic stroke.
* Significant confounding effects for rs152312 were atrial fibrillation, hypertension, diabetes 
and male gender. ^ Significant confounding effects for SNP 45 were atrial fibrillation and 
smoking.
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Table 4 shows the genotypes for SNP rs152312 and SNP 45 and their association with the 
cardioembolic stroke subtype (CE Stroke column) after important confounding factors were 
taken into account.  It demonstrates that the SNP rs152312 shows significant effects on 
cardioembolic stroke.  The odds ratios for the SNP (TT) versus the wild genotype (CC)
(OR=16.37, CI 1.69 to 127.8, p=0.01) and the combined non-wild genotypes (CT+TT) versus 
CC (OR=3.54, CI 1.05 to 12.33, p=0.04) for cardioembolic strokes are both significant.  There 
are also significant effects with SNP 45 and cardioembolic stroke after the confounding effects 
are taken into account for the combined non-wild (GA+AA) versus the wild (GG) genotype, 
although not significant for the single gene copy GA versus the wild genotype (p=0.09).  There 
is obviously no association with the non-cardioembolic stroke subgroup (labelled Non-CE 
Stroke in Table 4), nor was any association with the other four SNPs’ genotypes found (data 
not shown).
In the analysis of the other four SNPs, what appeared to be a third significant OR with the SNP 
13 ‘G’ allele and cardioembolic stroke (OR=0.360; C.I. 0.17 to 0.70, p=0.002) became non-
significant when adjusted for the confounding factors of atrial fibrillation, diabetes and 
hypertension (OR=0.45; C.I. 0.18 to 1.03, p=0.07) (data not shown).
















CC 243 (81) 14 (58) 1.00 125 (80) 1.00



















GG 206 (68) 23 (96) 1.00 105 (67) 1.00


















TABLE 4.  Analysis of SNPs between controls and stroke subtypes, after adjustment for 
significant confounders. * Significant confounding effects for rs152312 were atrial 
fibrillation, hypertension, diabetes and male gender. ^ Significant confounding effects for SNP 
45 were atrial fibrillation and smoking.
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Discussion 
In our study, after allowing for important confounders such as atrial fibrillation, significant 
odds ratios were found to be associated with cardioembolic strokes in SNPs rs152312 and 45 
(p<0.05).  We were powered sufficiently to show no association for any of the six SNPs with 
total ischemic stroke in our study. Although our subgroup analysis was not powered 
sufficiently to detect significant association with subgroups of ischemic stroke, we consider our 
findings overall add to the body of evidence supporting the hypothesis that PDE4D may 
contribute to the risk of cardioembolic stroke.
The SNP 41 used in the Gretarsdottir et al. study is actually rs12153798 (26), which showed 
links with combined cardiogenic and carotid stroke (5).  It was originally identified as 
rs152312, but this SNP, although studied by the Gretarsdottir group, was not reported in their 
supplementary tables as showing any association with stroke.  Due to the potential for 
confusion, we decided to use the nomenclature rs152312 rather than SNP41 in this paper.  Our 
SNP rs152312 data support the findings of Woo et al., who reported an association between 
rs152312 and cardioembolic stroke in their white US population (27).  However, in contrast to 
their reported association of SNP 87 with cardioembolic stroke, we found no association of 
SNP 87 with either cardioembolic stroke or total ischemic stroke.  
With respect to SNP 45, we found that when compared to the major ‘G’ allele, the non-wild 
‘A’ confers a protective effect (OR < 1) against having a cardioembolic stroke, either before or 
after adjustment for confounding factors.  A more recent Swedish study also found a protective 
association between SNP 45 and total ischemic stroke (28).  In contrast to both these studies, in 
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the original Icelandic study an at-risk or positive association (greater risk of stroke) was 
reported between SNP 45 and the combined cardiogenic and carotid stroke subtype patient 
groups (5).  Our finding is also in contrast with a study from USA that found the ‘A’ allele had 
a “non-significant at-risk effect” in non-hypertensive ischemic stroke patients (29).  A study in 
a Swedish population found a “non-significant link” between the ‘G’ allele and stroke which 
increased in the Large Artery Atherosclerosis (LAA) subtype of stroke, and was a component 
of a SNP 45-SNP 41 “GA” haplotype that showed a significant increased risk of stroke in both 
the  LAA group and for the combined LAA and cardioembolic group (30).  It remains to be 
seen if the protective effect of the non-‘G’ allele is due to an allele exchange between the 
Icelandic population’s ‘G’ allele and another nearby, undetected “at-risk” allele.
Our study is the second study of PDE4D in an Australian cohort with the first being in a 
population from the western state, whilst this study is from a southern state.  In the Western 
Australian study, the authors reported a significant association between PDE4D and ischemic 
stroke (19).  They also conducted a meta-analysis of nine case-controlled studies (including 
their own) that demonstrated a strong association with SNPs 41, 83 and 87.  They noted that 
there was statistical heterogeneity in the direction of the association between individual SNPs 
and stroke that suggested that the SNPs tested were in linkage disequilibrium with the causal 
alleles (19).  Some of the alleles we examined were also investigated by their study: SNPs 45, 
83 and 87.  For these SNPs, we report the same minor alleles, which the Western Australian 
authors noted were the converse of the at-risk alleles reported by Gretarsdottir et al.  In contrast 
with the Western Australian study which found an association of SNPs 83 and 87 with 
ischemic stroke (19), we found no association of these two SNPs with either total ischemic 
stroke or with subgroups.
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We assigned primers for rs152312 based on the original report detailing ‘SNP 41’ (5).  In the 
Genebank sequence gb|AC016607.6|AC016607 (Homo sapiens chromosome 5 clone CTD-
2165C), rs152312 is 175 base pairs distant from SNP 41.  Our chosen SNP rs152312, the 
correct SNP 41 (rs12153798) and SNP 45 are all contained within the promoter 1a isoform of 
the gene, being at relative positions in exon 1a of 144510, 144685 and 149009 respectively 
(31, 32).  Since SNP 41 and SNP 45 (4324 base pairs apart) are highly linked (r2 = 0.94) (31), 
the linkage between rs152312 and SNP 41 (only 175 base pairs apart) would be expected by 
genetic theory to be even greater. 
With regard to our finding of a lack of association between the SNP 13 ‘G’ allele and the 
cardioembolic stroke subtype (p=0.07), it is of interest to note that a previous association has 
been reported in the United Kingdom between homozygous ‘G’ SNP 13 alleles and 
cardioembolic stroke after controlling for risk factors (33).
As reported previously, the conventional risk factors of atrial fibrillation, smoking and diabetes 
are highly significant confounders affecting the risk of stroke (p<0.001) in all stroke patients 
(21).  In our present analysis of stroke subgroups, hypertension and male gender were also 
found to be significant confounders in strokes of cardioembolic origin, although they had no 
significant impact in the non-cardioembolic or total ischemic stroke groups (non-cardioembolic 
data not shown).
Populations of varied ethnic origins report different SNP frequencies for PDE4D in their 
control population.  For example, SNP 45 is one of two PDE4D SNPs that showed linkage in 
the original Icelandic population (5), but was found to be monomorphic in an Asian population 
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(34).  Data from our control group for SNP 87 demonstrated that the ‘T’ major allele frequency 
is 51.8%, very close to the 51.7% found in a United Kingdom study (33), but at slight variance 
to the dataset from Western Australia that showed a control population frequency of 56.1% 
(19).  Similarly, our control group had SNP 83 ‘C’ and SNP 45 ‘G’ frequencies of 57.7% and 
82.3%, respectively; the Western Australian dataset had frequencies of 60.1% and 86.3% (19).  
These variances in frequency may represent different sampling methods or differences in the
ethnic origins of the populations studied. 
In relation to the cardiogenic causes of strokes, aortic arch atherosclerosis (AAA) is an 
important source of cerebral emboli which may increase the risk for ischemic stroke (35).
Atherosclerotic plaques that are at least 4 mm in thickness in the aortic arch have been shown 
to be significant predictors of stroke and other vascular events (36).  Patients with severe AAA
have over four times the risk of stroke or peripheral embolism and recurrent stroke is also more 
common in this same patient group (37).  Indeed, the prevalence of severe AAA in stroke 
patients is over 20% (38).  One study of 100 consecutive patients with embolic cerebral 
ischemia of the internal carotid or vertebrobasilar arteries found a cardiac source of emboli in 
28% of their patients and AAA was found to be the probable source for embolic stroke in 14%
of patients (35). 
In our assessment of cardioembolic stroke, some patients may have had aortic arch 
atherosclerosis (AAA).  Cardioembolic stroke was defined as due to an intracardiac source, as 
determined by the neurologist, for example, atrial fibrillation, recent myocardial infarction or 
thrombus on cardiac imaging.  One plausible explanation is that there is coexistent AAA, but 
this was not actively investigated or assessed and requires further research.  We are unaware of 
any publications linking AAA with genetic risk. 
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Recent meta-analysis studies of different ethnic populations provide conflicting results with 
respect to the importance of the role of PDE4D in the polygenic risk of ischemic stroke (13, 28, 
31, 34).  However, the PDE4D gene has been postulated to contribute to large vessel disease 
through its role in inflammation and plaque stability, with changes involving processes that are 
important in the pathogenesis of atherosclerosis (5, 12).  As such, there is biological 
plausibility for the role of PDE4D in the pathogenesis of atherosclerosis and ischemic stroke, 
including strokes of cardiogenic origin.  Further prospective studies of PDE4D in different 
populations with larger sample numbers may help clarify the role of PDE4D in ischemic stroke 
and subtypes. 
Conclusion
We report new findings that SNP rs152312 and SNP 45 are associated with the cardioembolic
stroke subtype (p<0.05) in a mainly Caucasian population from South Australia.  However, we 
found no association of SNP 13, SNP 19, SNP 83 or SNP 87 with ischemic stroke in our study.  
This is the second Australian study to investigate PDE4D and ischemic stroke (19).  Our 
findings support the original Icelandic study suggesting SNP 45 in the PDE4D gene may be an 
important association in the cardioembolic subtype of ischemic stroke (5).  These findings add 
to the body of evidence supporting the hypothesis that PDE4D may contribute to the risk of 
cardiogenic stroke.  We propose that the results from our Australian study support the concept 
that a large, sufficiently powered, prospective international study is required to elucidate the 
role of PDE4D in cardioembolic ischemic stroke. 
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